Law360, New York (October 15, 2010, 2:58 PM ET) -- A Louisiana jury has smacked a Johnson & Johnson unit with a $257.7 million verdict in the state's suit against the company for downplaying the link between its antipsychotic drug Risperdal and diabetes.
The jury reached a verdict late Thursday in the 27th Judicial Court, St. Landry Parish, finding that J&J and its unit Janssen Pharmaceutica Inc. made misrepresentations in 2003 and 2004 about the drug's link to diabetes, according to Louisiana Attorney General James D. “Buddy” Caldwell.
“This verdict sends a loud message to those...
La. Jury Hits J&J With $258M Verdict In Risperdal Suit
To view the full article, take a free trial now.
